StreetAlpha.app
Home › Stocks › GHRS

GH Research PLC (GHRS)

Healthcare
Members
LATEST PRICE

GH Research develops mebufotenin-based treatments for depression and other psychiatric and neurological disorders. GHRS reports earnings on Thu, Nov 5, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).

Prices, price targets and earnings estimates for GHRS are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plans
AI Auto Pilots
Is GHRS in one of our four AI portfolios? Sign in free to see
See how it works→ Details ↓

Earnings

Earnings calendar →
Next report
Nov 5
2026 · Time not announced
Consensus EPS forecast
Members
EPS and revenue estimates
Year-ago EPS
Members
Same quarter last year
Options-implied move
Members
Move priced in by options
Analyst consensus
Strong Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
3firms
3 Buy0 Hold0 Sell
Each firm's latest rating on GHRS in the past 90 days
Average 12-month target
Price targets for GHRSThe average, highest and lowest analyst targets and the target chart are shown to AI Starter and AI Pro members.See plans
Latest rating changes
GuggenheimMaintained
Aug 7Buy
Cantor FitzgeraldMaintained
Aug 7Buy
NeedhamMaintained
Aug 6Buy
Wells FargoInitiated
Jul 27Buy
HC Wainwright & Co.Maintained
May 19Buy
DateFirmActionRatingPrice target
Aug 7GuggenheimMaintainedBuy
Aug 7Cantor FitzgeraldMaintainedBuy
Aug 6NeedhamMaintainedBuy
Jul 27Wells FargoInitiatedBuy
May 19HC Wainwright & Co.MaintainedBuy
Loading…

Seasonality

How GHRS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in GHRS in the last 90 days.

Loading…

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GHRS is in one of them and how their past GHRS trades turned out.

See how it works→ View all auto pilots→
GHRS in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered GHRS in an article yet. Here's the latest on the wider market.

macronewsFriday, October 30, 2026
Binance and Polymarket Hacks Test Crypto's Plumbing, Not Yet Macro
Binance paused withdrawals after a suspected theft of roughly $6 billion, while Polymarket halted trading for an hour after a vendor breach.
Jean Westart · 3 min read
macronewsMonday, October 26, 2026
S&P 500 Sits 2.5% Below Its Record Ahead of the Fed and Big Tech
The S&P 500 slipped 0.47% to 7,623.68, 2.5% below its record, as the Fed meets October 28 and Alphabet, Microsoft and Amazon report.
Marie Crown · 3 min read
macronewsMonday, October 26, 2026
Hightower's Stephanie Link Tells Investors to Add on Volatility
Hightower's Stephanie Link told CNBC's Squawk Box that investors should use market volatility to add to portfolios as earnings season unfolds.
Adam Landser · 2 min read

About GH Research

GH Research is a biopharmaceutical company based in Dublin, Ireland, that is developing treatments for psychiatric and neurological disorders. Its product candidates are based on mebufotenin, studied as an inhaled treatment called GH001 and as an intravenous treatment called GH002. The company's initial focus is treatment resistant depression, a form of major depressive disorder in which patients have not responded adequately to standard therapies. It has not yet received approval to sell any product, and its intended customers are patients with depression and the healthcare providers who treat them.

Headquarters
Dublin 2, Ireland
Summary based on the company’s 2026 annual report (20-F) ↗